Browse our comprehensive collection of market intelligence reports.
The bipolar disorder treatment landscape is entering a period of therapeutic diversification because unmet needs remain concentrated in bipolar depression, relapse prevention, and treatment-resistant disease. Existing mood stabilizers and atypical antipsychotics continue to dominate clinical practice, yet demand is shifting toward therapies that improve depressive symptoms without increasing metabolic burden or treatment discontinuation risk. This shift is increasing investment in novel mecha
The bipolar disorder drug pipeline is entering a transition phase because treatment demand increasingly centers on bipolar depression, relapse prevention, cognitive outcomes, and long-term tolerability rather than symptom suppression alone. Existing therapies remain dependent on mood stabilizers and atypical antipsychotics, while unmet needs continue to emerge across treatment-resistant populations and patients experiencing recurrent depressive episodes. Clinical development is therefore shif
The bipolar disorder pipeline is entering a period of therapeutic diversification because limitations associated with conventional mood stabilizers and atypical antipsychotics continue to create unmet needs across depressive episodes, maintenance therapy, treatment resistance, and agitation management. Demand increasingly focuses on therapies capable of improving depressive symptoms without triggering mania, which is shifting development activity toward novel receptor targets, glutamatergic p
The bipolar disorder clinical development landscape centers on the pursuit of therapies that address persistent unmet needs in bipolar depression, treatment-resistant disease, relapse prevention, and rapid symptom stabilization. Existing therapies provide symptom control for many patients, yet treatment discontinuation, inadequate response rates, metabolic adverse effects, and delayed onset of action continue to sustain demand for novel mechanisms.Clinical development activity is incre
The global spinal muscular atrophy (SMA) treatment landscape is shifting from a market dominated by survival-focused interventions toward a competitive ecosystem centered on functional improvement, long-term disease modification, and combination treatment strategies. SMA remains a rare genetic neuromuscular disorder caused by mutations in the SMN1 gene, creating sustained demand for therapies that restore survival motor neuron (SMN) protein expression and preserve motor neuron function.<p
The Global Spinal Muscular Atrophy (SMA) Emerging Therapies market centers on pipeline assets that seek to improve outcomes beyond survival motor neuron (SMN) restoration. The treatment landscape already contains approved SMN-targeted therapies, which shifts competitive demand toward assets capable of enhancing motor function, durability, and long-term quality of life.Development activity is increasingly focusing on combination strategies because residual functional limitations persist
The global spinal muscular atrophy (SMA) drug pipeline is entering a new phase in which developers are targeting residual disease burden that persists despite the availability of SMN-enhancing therapies. The market structure remains anchored around survival motor neuron (SMN) restoration, yet clinical demand is increasingly shifting toward combination strategies that address muscle function, motor performance, and long-term disease progression. This transition exists because treated patients
The global spinal muscular atrophy (SMA) pipeline is entering a second competitive cycle because disease-modifying therapies have altered survival outcomes and are shifting clinical expectations toward functional improvement, durability, and combination treatment strategies. The market now extends beyond survival and motor milestone preservation, creating demand for therapies that address residual muscle weakness, treatment resistance, and long-term disease management.Pipeline activity
The global spinal muscular atrophy (SMA) clinical trial landscape is entering a new phase in which development priorities extend beyond survival motor neuron (SMN) restoration and increasingly target functional recovery, muscle preservation, treatment durability, and post-gene-therapy optimization. The market structure centers on disease-modifying therapies, yet clinical demand is shifting toward combination approaches because a growing treated patient population continues to exhibit residual
The Artificial Intelligence (AI) in Medical Imaging Market comprises software platforms, algorithm development tools, and associated services that assist healthcare professionals in acquiring, processing, interpreting, and managing medical images across modalities such as computed tomography (CT), magnetic resonance imaging (MRI), X-ray, ultrasound, mammography, and positron emission tomography (PET). AI applications extend beyond image interpretation to workflow optimization, lesion quantifi
Mobile-wallet expansion and rising tap-to-pay acceptance directly increase demand for NFC controllers and secure elements across phones, wearables, and POS terminals. Regulatory support for tokenisation and higher contactless limits forces issuers to transition from legacy magnetic-stripe systems to dual-interface or secure-element-enabled cards, intensifying chip procurement. EU Digital Product Passport requirements drive adoption of memory-rich NFC tags for lifecycle traceability and authen
AMOLED technology employs an active-matrix thin-film transistor (TFT) array with storage capacitors, enabling large and high-resolution displays. Unlike LCDs, AMOLEDs do not require backlighting or color filters because they emit their own light, resulting in lower electricity consumption and higher image quality. However, their production costs are higher due to complexity.